Secant Group today announced what it described as game-changing technology to advance vascular regeneration, solving problems that surgeons presently have when it comes to vascular harvesting and the non-resorbable synthetic graft compliance mismatching.
The technology, which Secant (Telford, Pa.) developed in partnership with its sister company SanaVita Medical, involves a synthetic, small bore, vessel with a hollow lumen construct infused with Secant’s proprietary Regenerez bioresorbable polymer technology.
Early pre-clinical studies have shown the Regenerez grafts to be non-thrombogenic; they did not show occlusion and provide excellent suturability, according to Secant. Development continues with what Secant describes as a leading heart and vascular research university, and the company is looking for medical device company partners to advance the technology through clinical trials and commercialization.
Get the full story on our sister site Medical Design & Outsourcing.